Cytokinetics Q1 net loss widens to $131.3M; omecamtiv CRL; cuts spend 10%

CYTOKINETICS INC

2023-Q1 EPS reported -$1.38 revenue$4,613,000

Net loss of $131.3M ($1.38/shr) vs $89.4M ($1.05) in Q1 2022; revenue $4.6M (up from $1.1M).
Cash $704.4M; plans to reduce 2023 spending >10% to maintain >2 years cash runway.
FDA issued Complete Response Letter for omecamtiv mecarbil NDA; EMA MAA review ongoing.
SEQUOIA-HCM enrollment nearly complete; top-line results expected Q4 2023.
COURAGE-ALS met futility criteria; company discontinuing reldesemtiv treatment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYTOKINETICS INC reported the first quarter ended March 31, 2023 results: net income $131.3 million, EPS $1.38 per share.

Period: the first quarter ended March 31, 2023
Net income: $131.3 million
EPS: $1.38 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter was $131.3 million, or $1.38 per share, compared to net loss for the first quarter of 2022 of $89.4 million, or $1.05 per share.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-017822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.